ASX · ACR.AX
Acrux Limited
A$0.01A$0.00 (0.0%)
Acrux Limited’s quoted price sits in the lower half of its reported 52-week range, 52.38% below the high.
Loading market information…
OTC · PKTX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ProtoKinetix, Incorporated’s quoted price sits in the lower half of its reported 52-week range, 97.58% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow ProtoKinetix, Incorporated’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ProtoKinetix, Incorporated is a biotechnology firm engaged in research and development, specializing in the scientific and medical investigation of glycoproteins known as anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). These AFGPs are particularly relevant for their commercial potential within the healthcare sector, with a key area of their development involving utilizing AAGPs for the treatment of dry-eye conditions. Their research efforts are bolstered by a collaborative agreement with the University of British Columbia. Originally incorporated in 1999 as RJV Network, Inc., the company adopted its current name, ProtoKinetix, Incorporated, in July 2003. Its operational headquarters are situated in Marietta, Ohio.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.01A$0.00 (0.0%)
Acrux Limited’s quoted price sits in the lower half of its reported 52-week range, 52.38% below the high.
$0.21$0.00 (0.0%)
Zelira Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 50.78% below the high.
CA$0.32-CA$0.04 (-9.86%)
Grey Matters Health Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.44% below the high.
$0.00$0.00 (0.0%)
AXIM Biotechnologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.66% below the high.
$0.03$0.00 (0.0%)
Sigyn Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.5% below the high.
$0.00$0.00 (0.0%)
ReNeuron Group plc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Universal Ibogaine Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.97% below the high.
$0.00$0.00 (0.0%)
RepliCel Life Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.77% below the high.
